GSK and ViiV Healthcare confirmed today that the US District Court for the District of Delaware upheld the validity of a patent covering the double combination of lamivudine and abacavir (Epzicom®) and the triple combination of lamivudine, abacavir and zidovudine (Trizivir®).

This patent is U.S. Patent No. 6,417,191 B1, and it has an expiry date in March 2016.

Teva had previously acknowledged to the court that its generic version of Epzicom infringes the patent. There are no other challengers of this patent for Epzicom at this time.

In a separate component to the decision, the Judge ruled that the Lupin generic version of Trizivir did not infringe this combination patent. ViiV Healthcare is disappointed with this component of the court’s decision and intends to appeal.

Updated: 19 December 2013

Media contacts

For our corporate press office, email: Rachel Jaikaran

OR call +44 7823 523 755

For US-specific media enquiries,email:audrey.x.abernathy@viivhealthcare.com

OR call +1 919 605 4521

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.